David Seldin, MD, PhD
David Seldin, MD, PhD, has been appointed to the position of Chief of the Section of Hematology-Oncology in the Department of Medicine at Boston Medical Center (BMC). Dr. Seldin had served as Chief ad interim since January 2008.
Dr. Seldin joined the faculty of the department of medicine at Boston University School of Medicine (BUSM) in 1994 and was promoted to professor of medicine in 2005. He directs BUSM’s internationally renowned Amyloid Treatment and Research Program as well as the department of medicine’s Graduate Program in Molecular Medicine.
His research has defined the role of important intracellular signaling pathways in tumorigenesis and has identified novel approaches to the treatment of AL amyloidosis. Seldin has been continuously funded by the National Institutes of Health and has mentored 23 doctoral and predoctoral trainees.
Dr. Seldin is a member of several editorial boards, and regional and national committees. He has received a number of honors for his work including election to membership in the American Society of Clinical Investigation and mention on two “Best Doctor” lists.
“Dr. Seldin’s appointment is a defining moment in the history of our clinical programs in hematology and oncology,” said David Coleman, MD, Wade Professor and Chairman of the Department of Medicine at BUSM and physician-in-chief at BMC.
Dr. Seldin received his BA, MD and PhD degrees from Harvard University and served as a medical resident at Brigham and Women’s Hospital. He remained at Brigham and Women’s for his fellowship in hematology and oncology and for postdoctoral fellowship in the Department of Genetics at Harvard Medical School.